Roche Pharmaceutical Development and Sales Overview

Actemra/RoActemra Global sales CHFbn CER growth -23% Regional sales CER growth US -33% 3.0 2.5 Europe -3% 2.0 1.5 1.0 0.5 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 2,039m • US: Actemra SC share in RA keeps increasing; COVID-19 sales washed out as of Q3 • . EU: Market leadership in 1L RA monotherapy maintained; COVID-19 sales washed out as of Q3 International: COVID-19 sales washed out as of Q3 CER=Constant Exchange Rates Japan +1% International -39% Roche 155

View entire presentation